Drugs & Targets FDA grants accelerated approval to camizestrant combination for HR+ metastatic breast cancer September 11, 2026
Drugs & Targets FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC September 11, 2026
Drugs & Targets FDA approves first-of-its-kind drug rusfertide for polycythemia vera September 11, 2026
Podcast Raja Flores says oncology is loose with staging jargon, and now “it’s confusing my patients.” August 19, 2026
Drugs & TargetsFree FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma August 14, 2026Vol.52 No.32
Drugs & TargetsFree FDA advisory committee to vote on GRAIL’s multi-cancer detection test, Galleri August 14, 2026Vol.52 No.32
Drugs & TargetsFree FDA approves companion diagnostic supporting patients with advanced melanoma August 14, 2026Vol.52 No.32
Regulatory News FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committeeAmid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial August 07, 2026Vol.52 No.31By Jacquelyn Cobb and Paul Goldberg
